• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Insulet hits 52-week high on 1st positive cash flow

Insulet hits 52-week high on 1st positive cash flow

August 8, 2013 By Brad Perriello

Insulet soars on 1st positive cash flow

Insulet (NSDQ:PODD) shares spiked today after the medical device company reported record revenues for the 2nd quarter and said it logged its 1st positive quarterly cash flow.

Bedford, Mass.-based Insulet posted losses of $10.5 million, or 20¢ per share, on sales of $60.1 million for the 3 months ended June 30, lowering its losses by 27.3% and boosting sales by 17.7% compared with Q2 2012.

The losses per share beat expectations on Wall Street by a penny. That, and the positive cash flow, combined to send PODD shares to a 52-week high of $34.40 each today. The stock was up 10.4% to $33.86 apiece as of about 1:50 p.m.

"This was an outstanding quarter for Insulet, with demand for the new OmniPod exceeding our expectations," president & CEO Duane DeSisto said in prepared remarks. "With a greater than 50% year-over-year increase, we shipped a record-setting level of initial orders of the OmniPod in the 2nd quarter. This robust demand drove strong financial results, and we generated positive quarterly cash flow for the 1st time in Insulet’s history. Enthusiasm for the new OmniPod has been strong as the simplicity of the OmniPod’s smaller design, coupled with the updated insulin-on board methodology is appealing to both customers and healthcare professionals. We commenced the transition of our existing customer base to the new OmniPod in June and expect the vast majority of customers to be transitioned by the end of the 3rd quarter."

Insulet narrowed its sales outlook for the rest of the year, saying it now expects revenues of $242 million to $252 million, from prior guidance of $240 million to $255 million. Third-quarter sales are pegged at $60 million to $64 million. Both guidances assume a $5 million hit during both the 3rd and 4th quarters on the impact of Medicare’s Round 2 competitive bidding program, according to a press release.

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: 2013, Insulet, Q2

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy